Estella Mendelson

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib <i>versus</i> best available therapy

Claire Harrison, Ruben A. Mesa, Jean‐Jacques Kiladjian et al. · British Journal of Haematology · 2013 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

Keith L. Davis, Isabelle Côté, James A. Kaye et al. · Advances in Hematology · 2015 · 26 citations · Full text

Medicine, Hematology, Internal Medicine +13

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

Carla Boquimpani, Tomasz Szczudlo, Estella Mendelson et al. · Blood · 2014 · 21 citations

Medicine, Oncology, Chemotherapy +3

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

Matthew Squires, Claire Harrison, Giovanni Barosi et al. · Blood · 2013 · 18 citations

Life Sciences, Hematology, Immunology +16

Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

Jörge E. Cortes, Lynn Huynh, Estella Mendelson et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 15 citations

Medicine, Oncology, Pharmacology +11